MedGenome Partners with Adaptive Biotechnologies to Offer ClonoSEQ Assay for Minimal Residual Disease Assessment
ClonoSEQ Assay: Detecting and Monitoring Minimal Residual Disease (MRD) in Blood Cancer
MRD is described as the number of very small cancer cells that remain in the body during or after treatment. The number of remaining cells can be so small that they do not show any physical signs or symptoms and often can go undetected through traditional methods. The clonoSEQ test may effectively detect and monitor MRD in patients with certain types of blood cancer. It helps to detect MRD even at low levels offering a prognostic value to clinicians, helping them to assess how patients respond to treatment or if any change in disease management is required.
Enhanced Sensitivity and Monitoring of Minimal Residual Disease (MRD) with ClonoSEQ Assay
The test determines MRD at very low levels (10-6 sensitivity) as compared to other currently available assays for MRD detection and therefore imparts benefit to a larger number of patients. The test identifies dominant immune cell clones at the time of high disease burden that can be monitored after the treatment to determine MRD.
MedGenome Introduces ClonoSEQ Assay in India, Advancing Precision Medicine for Blood Cancer Treatment
Vedam Ramprasad, PhD, Chief Executive Officer (India) of MedGenome Labs said, “At MedGenome, we have always been at the forefront of bringing innovative technologies in genomics, aiding clinicians to choose the right treatment/management regime for patients. We are excited to introduce clonoSEQ in India. This will be a valuable tool in monitoring treatment decisions leading to better patient outcomes across multiple types of blood cancers.”
Adaptive Biotechnologies and MedGenome Collaborate to Bring clonoSEQ Assay to Patients in India for Improved Disease Management
Nitin Sood, Chief Commercial Officer, MRD, of Adaptive Biotechnologies said, “We are excited that MedGenome will be able to offer clonoSEQ to patients in India living with lymphoid malignancies. MRD assessment with clonoSEQ is a critical tool for physicians and patient to manager their disease.”
Read More: In-Vitro Diagnostics: Technology Trends For 2023 And Other Details